Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve

ObjectiveTo evaluate whether methotrexate (MTX) compromises ovarian reserve and future reproductive outcome in women undergoing assisted reproductive technology (ART), when it is used as first-line treatment for ectopic pregnancy (EP).DesignProspective, observational study.SettingUniversity-affiliated private IVF unit.Patient(s)Twenty-five women undergoing IVF-ICSI who were treated with MTX (1 mg/kg IM) for an EP after ART.Intervention(s)Evaluation of reproductive outcome and serum anti-Müllerian hormone (AMH) levels. Serum AMH was evaluated before administering MTX and ≥1 week after the resolution of the EP. Reproductive outcome was evaluated by comparing subsequent IVF-ICSI cycles after EP resolution.Main Outcome Measure(s)Serum AMH levels, cycle length, gonadotropin dose required, peak serum E2 level, oocytes collected, and embryos obtained.Result(s)Serum AMH levels before MTX were not statistically significantly different from those after treatment (3.7 ± 0.3 ng/mL vs. 3.9 ± 0.3 ng/mL). Patients undergoing a subsequent cycle after systemic treatment for EP had similar cycle durations (10.3 vs. 10.8 d), gonadotropin requirements (2,775 vs. 2,630.3 IU), peak E2 levels (1,884.3 vs. 1,523.6 pg/mL), number of oocytes retrieved (12.1 vs. 10.5), and total number of embryos obtained (7.1 vs. 6.5).Conclusion(s)Single-dose MTX is a safe first-treatment choice that does not compromise future reproductive outcomes in women who are diagnosed with EP after ART.